Gravar e-mail: P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY